Table A2.
Characteristics of 1,575 Caucasian subjects (Phase 1), Mayo Clinic, and Duke University.
| Mayo Clinic |
Duke University |
|||
|---|---|---|---|---|
| Cases (n = 312) | Controls (n = 439) | Cases (n = 343) | Controls (n = 481) | |
| Age, years [mean (SD)] | 60.8 (12.8) | 60.0 (12.9) | 56.8 (10.4) | 54.6 (12.0) |
| BODY MASS INDEX, kg/m2 | ||||
| <23 [n (%)] | 57 (18.5) | 103 (23.7) | 96 (29.0) | 132 (28.1) |
| 23–26 [n (%)] | 77 (24.9) | 125 (28.8) | 85 (25.7) | 117 (25.0) |
| 26–29 [n (%)] | 61 (19.7) | 88 (20.3) | 75 (22.7) | 110 (23.5) |
| ≥29 [n (%)] | 114 (36.9) | 118 (27.2) | 75 (22.7) | 110 (23.5) |
| AGE AT MENARCHE, year | ||||
| <12 [n (%)] | 46 (18.5) | 67 (15.7) | 88 (25.7) | 85 (17.7) |
| 12 [n (%)] | 60 (24.1) | 97 (22.8) | 99 (29.0) | 142 (29.5) |
| 13 [n (%)] | 66 (26.5) | 126 (29.6) | 82 (24.0) | 140 (29.1) |
| ≥14 [n (%)] | 77 (30.9) | 136 (31.9) | 73 (21.4) | 114 (23.7) |
| ORAL CONTRACEPTIVE USE, months | ||||
| Never [n (%)] | 150 (49.7) | 166 (38.9) | 116 (34.5) | 148 (31.0) |
| 1–48 [n (%)] | 75 (24.8) | 90 (21.1) | 105 (31.3) | 133 (27.8) |
| ≥48 [n (%)] | 77 (25.5) | 171 (40.1) | 115 (34.2) | 197 (41.2) |
| POSTMENOPAUSAL STATUS | ||||
| Yes [n (%)] | 222 (73.0) | 328 (75.1) | 251 (80.2) | 312 (66.1) |
| POSTMENOPAUSAL HORMONE USE, months | ||||
| Never [n (%)] | 193 (62.7) | 244 (58.5) | 108 (33.4) | 270 (59.3) |
| 1–60 [n (%)] | 54 (17.5) | 79 (18.9) | 114 (35.3) | 96 (21.1) |
| ≥60 [n (%)] | 61 (19.8) | 94 (22.5) | 101 (31.3) | 89 (19.6) |
| PARITY, n/age at first birth, year | ||||
| Nulliparous [n (%)] | 56 (18.0) | 64 (14.7) | 71 (20.7) | 64 (13.3) |
| 1–2/≤20 [n (%)] | 20 (6.4) | 24 (5.5) | 46 (13.4) | 57 (11.9) |
| 1–2/≥20 [n (%)] | 91 (29.2) | 130 (29.9) | 125 (36.4) | 211 (43.9) |
| ≥3/≤20 [n (%)] | 59 (18.9) | 63 (14.5) | 49 (14.3) | 61 (12.7) |
| ≥3/≥20 [n (%)] | 86 (27.6) | 154 (35.4) | 52 (15.2) | 88 (18.3) |
| FAMILY HISTORY OF OVARIAN CANCERa | ||||
| Yes [n (%)] | 41 (13.1) | 33 (7.5) | 33 (9.6) | 26 (5.4) |
| SMOKING, pack-years | ||||
| None [n (%)] | 194 (65.3) | 279 (68.2) | 190 (57.8) | 250 (54.1) |
| ≤20 [n (%)] | 56 (18.9) | 82 (20.1) | 80 (24.3) | 121 (26.2) |
| >20 [n (%)] | 47 (15.8) | 48 (11.7) | 59 (17.9) | 91 (19.7) |
| EDUCATION | ||||
| No diploma [n (%)] | 18 (6.1) | 19 (4.3) | 26 (7.6) | 42 (8.7) |
| High School diploma [n (%)] | 107 (36.2) | 116 (26.5) | 105 (30.6) | 131 (27.2) |
| Post-high school education [n (%)] | 171 (57.8) | 303 (69.2) | 212 (61.8) | 308 (64.0) |
| MULTIVITAMIN USEb | ||||
| Yes [n (%)] | 73 (39.9) | 217 (51.7) | 115 (35.0) | 161 (34.6) |
| TUMOR HISTOLOGY, CASES | ||||
| Serous [n (%)] | 191 (61.2) | 206 (60.2) | ||
| Mucinous [n (%)] | 8 (2.6) | 19 (5.7) | ||
| Endometrioid [n (%)] | 63 (20.2) | 53 (15.5) | ||
| Clear cell [n (%)] | 20 (6.4) | 28 (8.2) | ||
| Other [n (%)] | 30 (9.6) | 36 (10.5) | ||
Counts do not total to 1,575 subjects due to missing data for some variables.
aIn first- or second-degree relative.
bAt least four pills per week during the previous year for at least 48 months’ duration of lifetime use (Mayo Clinic subjects) or at least three pills per week for at least 48 months during the past 60 months (Duke University subjects).